EMA Authorised: Lenvima (lenvatinib mesilate) — Eisai GmbH

View source ↗

Summary

EMA authorised Lenvima (lenvatinib mesilate) by Eisai GmbH for thyroid neoplasms, under accelerated assessment, with a decision dated 26 March 2026.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thyroid Neoplasms

Drugs mentioned

• LENVIMA (lenvatinib)

Snippet

Status: Authorised. Therapeutic area: Thyroid Neoplasms. MAH: Eisai GmbH. Decision date: 26/03/2026. Accelerated assessment